|
1
|
Ho FC, Tham IW, Earnest A, et al: Patterns
of regional lymph node metastasis of nasopharyngeal carcinoma: a
meta-analysis of clinical evidence. BMC Cancer. 12:982012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Golubovskaya VM, Conway-Dorsey K, Edmiston
SN, et al: FAK overexpression and p53 mutations are highly
correlated in human breast cancer. Int J Cancer. 125:1735–1738.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Olivier M, Eeles R, Hollstein M, et al:
The IARC TP53 database: new online mutation analysis and
recommendations to users. Hum Mutat. 19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kondo I, Iida S, Takagi Y and Sugihara K:
MDM2 mRNA expression in the p53 pathway may predict the potential
of invasion and liver metastasis in colorectal cancer. Dis Colon
Rectum. 51:1395–1402. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sunavala-Dossabhoy G, Palaniyandi S, Clark
C, et al: Analysis of eIF4E and 4EBP1 mRNAs in head and neck
cancer. Laryngoscope. 121:2136–2141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh J, Jayaraj R, Baxi S, Mileva M,
Curtin J and Thomas M: An Australian retrospective study to
evaluate the prognostic role of p53 and eIF4E cancer markers in
patients with head and neck squamous cell carcinoma (HNSCC): study
protocol. Asian Pac J Cancer Prev. 14:4717–4721. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yin X, Kim RH, Sun G, Miller JK and Li BD:
Overexpression of eukaryotic initiation factor 4E is correlated
with increased risk for systemic dissemination in node-positive
breast cancer patients. J Am Coll Surg. 218:663–671. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Von Pawel J: Gefitinib (Iressa, ZD1839): a
novel targeted approach for the treatment of solid tumors. Bull
Cancer. 91:E70–E76. 2004.PubMed/NCBI
|
|
9
|
Feng M, Wang W, Fan Z, Fu B, Li J, Zhang S
and Lang J: Tumor volume is an independent prognostic indicator of
local control in nasopharyngeal carcinoma patients treated with
intensity-modulated radiotherapy. Radiat Oncol. 8:2082013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greene FL, Page DL, et al: AJCC Cancer
Staging Manual. 6th edition. Springer; New York, NY: pp. 47–60.
2002
|
|
11
|
Lee AW, Lin JC and Ng WT: Current
management of nasopharyngeal cancer. Semin Radiat Oncol.
22:233–244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berg M and Soreide K: EGFR and downstream
genetic alterations in KRAS/BRAF and PI3K/AKT pathways in
colorectal cancer: implications for targeted therapy. Discov Med.
14:207–214. 2012.PubMed/NCBI
|
|
13
|
Baselga J: The EGFR as a target for
anticancer therapy - focus on cetuximab. Eur J Cancer. 37:S16–S22.
2001. View Article : Google Scholar
|
|
14
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meek DW: Tumour suppression by p53: a role
for the DNA damage response? Nat Rev Cancer. 9:714–723.
2009.PubMed/NCBI
|
|
16
|
Chang LJ and Eastman A: Decreased
translation of p21 (waf1) mRNA causes attenuated p53 signaling in
some p53 wild-type tumors. Cell Cycle. 11:1818–1826. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seong HA and Ha H: Murine protein
serine/threonine kinase 38 activates p53 function through Ser15
phosphorylation. J Biol Chem. 287:20797–20810. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin Y, Stephen CW, Luciani MG, et al: p53
stability and activity is regulated by mdm2-mediated induction of
alternative p53 translation products. Nat Cell Biol. 46:462–467.
2002. View
Article : Google Scholar
|
|
19
|
Camus S, Ménendez S, Fernandes K, et al:
The p53 isoforms are differentially modified by Mdm2. Cell Cycle.
11:1646–1655. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang L, Yan Z, Liao X, et al: The p53
inhibitors MDM2/MDMX complex is required for control of p53
activity in vivo. Proc Natl Acad Sci. 108:12001–12006. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nicholson J and Hupp TR: The molecular
dynamics of MDM2. Cell Cycle. 9:1878–1881. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
De Benedetti A and Graff JR: eIF-4E
expression and its role in malignancies and metastases. Oncogene.
23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zimmer SG, DeBenedetti A and Graff JR:
Translational control of malignancy: the mRNA cap-binding protein,
eIF-4E, as a central regulator of tumor formation, growth, invasion
and metastasis. Anticancer Res. 20:1343–1351. 2000.PubMed/NCBI
|
|
24
|
Stark AM, Hugo HH, Witzel P, et al:
Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma
multiforme. Zentralbl Neurochir. 64:30–36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ushio Y, Tada K, Shiraishi S, et al:
Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN,
and EGFR and survival of patients with anaplastic astrocytoma and
glioblastoma. Front Biosci. 1:281–288. 2003. View
Article : Google Scholar
|
|
26
|
Halatsch ME, Schmidt U, Unterberg A and
Vougioukas VI: Uniform MDM2 overexpression in a panel of
glioblastoma multiforme cell lines with divergent EGFR and p53
expression status. Anticancer Res. 26:4191–4194. 2006.
|
|
27
|
Pan J, Tang T, Xu L, et al: Prognostic
significance of expression of cyclooxygenase-2, vascular
endothelial growth factor, and epidermal growth factor receptor in
nasopharyngeal carcinoma. Head Neck. 35:1238–1247. 2013. View Article : Google Scholar
|
|
28
|
Esteve A, Lehman T, Jiang W, et al:
Correlation of p53 mutations with epidermal growth factor receptor
overexpression and absence of mdm2 amplification in human
esophageal carcinomas. Mol Carcinog. 8:306–311. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deb SP, Muñoz RM, Brown DR, et al:
Wild-type human p53 activates the human epidermal growth factor
receptor promoter. Oncogene. 9:1341–1349. 1994.PubMed/NCBI
|
|
30
|
Korkolopoulou P, Christodoulou P, Kouzelis
K, et al: MDM2 and p53 expression in gliomas: a multivariate
survival analysis including proliferation markers and epidermal
growth factor receptor. Br J Cancer. 75:1269–1278. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harada K, Kurisu K, Tahara H, et al:
Telomerase activity in primary and secondary glioblastomas
multiforme as a novel molecular tumor marker. J Neurosurg.
93:618–625. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Halatsch ME, Schmidt U, Botefur IC, et al:
Overexpression of deletion-mutant epidermal growth factor receptor
is associated with altered genotoxic stress-provoked p53 mRNA
induction in a human glioblastoma cell line. Anticancer Res.
21:189–195. 2001.PubMed/NCBI
|
|
33
|
Kleihues P and Ohgaki H: Primary and
secondary glioblastomas: from concept to clinical diagnosis. Neuro
Oncol. 1:44–51. 1999.
|
|
34
|
Stark AM, Hugo HH, Witzel P, et al:
Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma
multiforme. Zentralbl Neurochir. 64:30–36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Houillier C, Lejeune J, Benouaich-Amiel A,
et al: Prognostic impact of molecular markers in a series of 220
primary glioblastomas. Cancer. 106:2218–2223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dehais C, Laigle-Donadey F, Marie Y, et
al: Prognostic stratification of patients with anaplastic gliomas
according to genetic profile. Cancer. 107:1891–1897. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ruano Y, Ribalta T, de Lope AR, et al:
Worse outcome in primary glioblastoma multiforme with concurrent
epidermal growth factor receptor and p53 alteration. Am J Clin
Path. 131:257–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ruiz C, Seibt S, Al Kuraya K, et al:
Tissue microarrays for comparing molecular features with
proliferation activity in breast cancer. Int J Cancer.
118:2190–2194. 2006. View Article : Google Scholar
|
|
39
|
Berghmans T, Mascaux C, Haller A, et al:
EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung
cancer: a positive association. Lung Cancer. 62:35–44. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schaefer IM, Sahlmann CO, Overbeck T, et
al: Blastomatoid pulmonary carcinosarcoma: report of a case with a
review of the literature. BMC Cancer. 12:4242012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vasei M, Modjtahedi H, Ale-Booyeh O, et
al: Amplification and expression of EGFR and ERBB2 in Wilms tumor.
Cancer Genet Cytogenet. 194:88–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wiseman SM, Masoudi H, Niblock P, et al:
Anaplastic thyroid carcinoma: expression profile of targets for
therapy offers new insights for disease treatment. Ann Surg Oncol.
14:719–729. 2007. View Article : Google Scholar
|
|
43
|
Baffa R, Letko J, McClung C, LeNoir J,
Vecchione A and Gomella LG: Molecular genetics of bladder cancer:
targets for diagnosis and therapy. J Exp Clin Cancer Res.
25:145–160. 2006.PubMed/NCBI
|
|
44
|
Bianco R, Caputo R, Caputo R, Damiano V,
De Placido S, Ficorella C, et al: Combined targeting of epidermal
growth factor receptor and MDM2 by gefitinib and antisense MDM2
cooperatively inhibit hormone-independent prostate cancer. Clin
Cancer Res. 10:4858–4864. 2004. View Article : Google Scholar : PubMed/NCBI
|
